Clinical Trials Logo

Clinical Trial Summary

This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)


Clinical Trial Description

This phase 1b, Open-Label Study will assess the safety, efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). Patients who meet the criteria for the study CORT-118335-861 will be enrolled on Day 1 into 1 of 4 cohorts and receive miricorilant, escalated every 4 weeks, from 150mg once daily, to 600mg once daily, in 150mg increments over 16 weeks or a steady dose of either 150mg, 300mg or 450mg miricorilant once daily, for up to 12 weeks. ;


Study Design


Related Conditions & MeSH terms

  • Fatty Liver
  • Non-alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis (NASH)

NCT number NCT05117489
Study type Interventional
Source Corcept Therapeutics
Contact Clinical Trial Lead
Phone 650-327-3270
Email [email protected]
Status Recruiting
Phase Phase 1
Start date November 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04880031 - A Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04104321 - A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) Phase 3
Completed NCT02891408 - Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function Phase 1
Completed NCT04546984 - Multiple Dose Safety, Tolerability, PK,PD and Food Effect Study of HEC96719 in Healthy Adult Subjects Phase 1
Completed NCT02854605 - Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT03572465 - Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Terminated NCT03823703 - Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04165343 - Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Recruiting NCT04913090 - A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects Phase 1
Terminated NCT04004325 - A Study of FT 4101 in Overweight/Obese Participants With NASH Phase 1/Phase 2
Completed NCT01265498 - The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) Phase 2
Terminated NCT00845845 - Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04267393 - Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04616014 - A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT01638832 - Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease N/A
Completed NCT02443116 - Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2
Completed NCT02808312 - Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Phase 1
Completed NCT02781584 - Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2
Completed NCT02196831 - Tesamorelin Effects on Liver Fat and Histology in HIV N/A
Completed NCT03392779 - Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics Phase 1